Update on Lawsuit Against Amgen Inc. (NASDAQ: AMGN): Long-Term Investors Advised to Contact Shareholders Foundation

0
2

Lawsuit Pending for Investors in Amgen Inc. (NASDAQ: AMGN) Shares – Contact Shareholders Foundation for Information

Amgen Inc. (NASDAQ: AMGN) Faces Lawsuit Over Alleged Tax Issues

Investors in Amgen Inc. (NASDAQ: AMGN) are facing uncertainty as a lawsuit is pending over alleged securities laws violations. The U.S. government claims that Amgen owes billions of dollars in back taxes for multiple tax years, leading to a substantial risk of severe financial penalties from the IRS.

A NASDAQ: AMGN investor filed a lawsuit against Amgen Inc. on March 13, 2023, alleging that the company made false and misleading statements regarding its tax obligations. The plaintiff claimed that the U.S. government is seeking over $3 billion in back taxes for tax years 2010-2012 and over $5 billion for tax years 2013-2015. Additionally, it is believed that Amgen may owe even more in subsequent tax years.

Amgen filed a motion to dismiss the case on November 6, 2023, and a court hearing was held on July 18, 2024, regarding the motion to dismiss. Investors who purchased shares of Amgen Inc. (NASDAQ: AMGN) prior to July 2020 and still hold those shares have certain options available to them and are encouraged to contact the Shareholders Foundation, Inc. for more information.

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and settlement claim filing service that provides information on shareholder issues, securities class actions, settlements, and other legal news related to the stock market. Investors should be aware of the potential risks associated with investing in companies facing legal challenges like Amgen.

For more information, investors can contact the Shareholders Foundation, Inc. at mail@shareholdersfoundation.com or call +1 (858) 779-1554.

Source: Shareholders Foundation, Inc.